✦ LIBER ✦

Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma : Results of a phase 2 study

✍ Scribed by Giuseppe Lombardi; Fable Zustovich; Fabio Farinati; Umberto Cillo; Alessandro Vitale; Giacomo Zanus; Martin Donach; Miriam Farina; Stefania Zovato; Davide Pastorelli

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 150 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25578

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of pegylated liposomal dox

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

Phase II study of gemcitabine in patient

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

✍ Tai-Shen Yang; Yung-Chang Lin; Jen-Shi Chen; Hung-Ming Wang; Chen-Hsu Wang 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 3 views

Phase I dose and sequencing study of peg

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies

✍ Paula M. Fracasso; Luis C. Rodriguez; Thomas J. Herzog; Carole L. Fears; Sherry 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad

Gemcitabine plus oxaliplatin (GEMOX) in

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) : Results of a phase II study

✍ Samy Louafi; Valérie Boige; Michel Ducreux; Luminita Bonyhay; Touraj Mansourbakh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

A phase II trial of gemcitabine in patie

A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma

✍ Charles S. Fuchs; Jeffrey W. Clark; David P. Ryan; Mathew H. Kulke; Haesook Kim; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract ## BACKGROUND There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerabili

Phase 2 study of cetuximab in patients w

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

✍ Andrew X. Zhu; Keith Stuart; Lawrence S. Blaszkowsky; Alona Muzikansky; Donald P 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. ## METHODS.